Long-term medical management of endometriosis with dienogest and with a gonadotropin-releasing hormone agonist and add-back hormone therapy.
Endometriosis can recur after either surgical or medical therapy. Long-term medical therapy is implemented to treat symptoms or prevent recurrence. Dienogest and gonadotropin-releasing hormone (GnRH) analogues with hormone add-back therapy seem to be equally effective for long-term treatment of pain symptoms associated with endometriosis. There is insufficient evidence to support the superiority of one therapy over the other. However, add-back hormone therapy (HT) is recommended for patients using GnRH agonists. The treatment selection depends on therapeutic effectiveness, tolerability, drug cost, the physician's experience, and expected patient compliance.
['Bedaiwy|Mohamed A|MA|', 'Allaire|Catherine|C|', 'Alfaraj|Sukinah|S|']
D000293:Adolescent D000328:Adult D000367:Age Factors D003277:Contraceptives, Oral, Combined D003362:Cost-Benefit Analysis D016527:Drug Costs D004359:Drug Therapy, Combination D004715:Endometriosis D004717:Endometrium D005260:Female D007987:Gonadotropin-Releasing Hormone D006801:Humans D055118:Medication Adherence D009277:Nandrolone D017699:Pelvic Pain D011372:Progestins D012008:Recurrence D016896:Treatment Outcome D055815:Young Adult
endometriosis Dienogest hormone add-back GnRH-a long term